Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report available @ Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG AbbVie Inc. Acetylon Pharmaceuticals, Inc. Altor BioScience Corporation Amgen Inc. Aprogen, Inc. Arno Therapeutics, Inc. Astellas Pharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Bayer AG BeiGene(Beijing) Co.,Ltd Bellicum Pharmaceuticals, Inc. Biogen, Inc. BioInvent International AB Bionovis SA Biothera, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cellectis S.A. Cellular Biomedicine Group, Inc. Coherus BioSciences, Inc. CTI BioPharma Corp. Cyclacel Pharmaceuticals, Inc. Eli Lilly and Company Emergent BioSolutions Inc. Epirus Biopharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Genentech, Inc. Genor BioPharma Co., Ltd. Gilead Sciences, Inc. Grupo Ferrer Internacional, S.A. Hospira, Inc. Hutchison MediPharma Limited Hybrigenics S.A. Igenica Biotherapeutics, Inc. ImmunoGen, Inc. Immunomedics, Inc. Incyte Corporation Infinity Pharmaceuticals, Inc. Inflection Biosciences Limited Innate Pharma SA Innovent Biologics, Inc. Johnson & Johnson Juno Therapeutics Inc. KAEL-GemVax Co., Ltd. KaloBios Pharmaceuticals, Inc. Kancera AB Karyopharm Therapeutics, Inc. Kite Pharma, Inc. Lead Discovery Center GmbH Les Laboratoires Servier SAS LFB S.A. Lymphocyte Activation Technologies, S.A. Medicenna Therapeutics, Inc MediGene AG MedImmune, LLC MENTRIK Biotech, LLC Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals, Inc. Mirna Therapeutics, Inc. Molecular Templates Inc. MorphoSys AG NantKwest, Inc. Novartis AG Ono Pharmaceutical Co., Ltd. Onyx Pharmaceuticals, Inc. Panacea Biotec Limited PEP-Therapy SAS Pharmacyclics, Inc. Portola Pharmaceuticals, Inc. Redx Pharma Plc Respiratorius AB Sandoz International GmbH Sanofi Selvita SA Shanghai Henlius Biotech Co., Ltd. Simcere Pharmaceutical Group Sorrento Therapeutics, Inc. Supratek Pharma Inc. Targazyme, Inc. TG Therapeutics, Inc. The International Biotechnology Center (IBC) Generium Theravectys SA Threshold Pharmaceuticals, Inc. Tolero Pharmaceuticals, Inc. Tragara Pharmaceuticals, Inc. ViDAC Pharma Ltd. Viralytics Ltd. Zymeworks Inc.
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report available @ Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG AbbVie Inc. Acetylon Pharmaceuticals, Inc. Altor BioScience Corporation Amgen Inc. Aprogen, Inc. Arno Therapeutics, Inc. Astellas Pharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Bayer AG BeiGene(Beijing) Co.,Ltd Bellicum Pharmaceuticals, Inc. Biogen, Inc. BioInvent International AB Bionovis SA Biothera, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cellectis S.A. Cellular Biomedicine Group, Inc. Coherus BioSciences, Inc. CTI BioPharma Corp. Cyclacel Pharmaceuticals, Inc. Eli Lilly and Company Emergent BioSolutions Inc. Epirus Biopharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Genentech, Inc. Genor BioPharma Co., Ltd. Gilead Sciences, Inc. Grupo Ferrer Internacional, S.A. Hospira, Inc. Hutchison MediPharma Limited Hybrigenics S.A. Igenica Biotherapeutics, Inc. ImmunoGen, Inc. Immunomedics, Inc. Incyte Corporation Infinity Pharmaceuticals, Inc. Inflection Biosciences Limited Innate Pharma SA Innovent Biologics, Inc. Johnson & Johnson Juno Therapeutics Inc. KAEL-GemVax Co., Ltd. KaloBios Pharmaceuticals, Inc. Kancera AB Karyopharm Therapeutics, Inc. Kite Pharma, Inc. Lead Discovery Center GmbH Les Laboratoires Servier SAS LFB S.A. Lymphocyte Activation Technologies, S.A. Medicenna Therapeutics, Inc MediGene AG MedImmune, LLC MENTRIK Biotech, LLC Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals, Inc. Mirna Therapeutics, Inc. Molecular Templates Inc. MorphoSys AG NantKwest, Inc. Novartis AG Ono Pharmaceutical Co., Ltd. Onyx Pharmaceuticals, Inc. Panacea Biotec Limited PEP-Therapy SAS Pharmacyclics, Inc. Portola Pharmaceuticals, Inc. Redx Pharma Plc Respiratorius AB Sandoz International GmbH Sanofi Selvita SA Shanghai Henlius Biotech Co., Ltd. Simcere Pharmaceutical Group Sorrento Therapeutics, Inc. Supratek Pharma Inc. Targazyme, Inc. TG Therapeutics, Inc. The International Biotechnology Center (IBC) Generium Theravectys SA Threshold Pharmaceuticals, Inc. Tolero Pharmaceuticals, Inc. Tragara Pharmaceuticals, Inc. ViDAC Pharma Ltd. Viralytics Ltd. Zymeworks Inc.
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 20:33
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home